Thursday, November 1, 2018 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in modern drug development at the Supply Side West Conference in Las Vegas, 8-9 of November.
Artificial Intelligence techniques (AI), such as deep learning (DL), reinforcement learning (RL), and generative adversarial networks (GANs), - generating as much data as possible - can be used to invent entirely new products. At Insilico AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, AI helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of geroprotectors.
"We were one of the first groups to start using AI to predict the effects of the nutraceuticals and launch a range of products with a nutraceutical company. We are happy to present our results at the Supply Side Conference, which gathers the key industry leaders. The topic of AI for drug development is rapidly gaining popularity, and we are happy to be at the leading edge of research and one of the innovation drivers in the area", says Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
In addition the company intends to announce a key research partnership with one of the leading organizations in evidence-based products for longevity biotechnology. Through its Young.AI system Insilico Medicine provides a range of research tools for the aging research community and enables a variety of research collaborations.
Supply Side West Conference brings together the largest health&nutrition industry professionals focused on dietary supplement, beverage, functional food, personal care, and sports nutrition innovation to drive their innovation, growth, and profitability, with input from purchasing, product development, marketing, supply chain management and more. The Conference is held on 6-10 of November.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine.
For further information, images or interviews, please contact:
Contact: Klug Gehilfer
Official website of the conference:
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/